-
3 US Generics and Branded Medicines Company, Pain and Anti-Malarial Brands Leader and Soft Gel Capsules Producer Stocks With a Strong Future Roadmap: Alembic Pharmaceuticals, Ipca Laboratories and Strides Pharma Science
- October 27, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
No Comments
US Generics, Pain Care Brand and Soft Gel Stocks with a strong future roadmap: Alembic Pharmaceuticals, Ipca Laboratories and Strides Pharma Science. Compare price, valuation, return on equity and revenue growth as of 26 October 2026.
-
3 US Generics Formulations Maker, Respiratory and Anti-Infective Leader and Contract Formulations Producer Stocks With a Strong Future Roadmap: Strides Pharma Science, Cipla and Innova Captab
- October 27, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
US Generics, Respiratory and Contract Stocks with a strong future roadmap: Strides Pharma Science, Cipla and Innova Captab. Compare price, valuation, return on equity and revenue growth as of 26 October 2026.
-
3 Regulated-Market Generics Maker, Specialty Branded Generics Seller and Large Active Ingredients Producer Stocks With a Strong Future Roadmap: Strides Pharma Science, Ajanta Pharma and Divi’s Laboratories
- October 26, 2026
- Posted by: Lakshit Sharma
- Category: Best Stocks
Generic Formulation and API Pharma Stocks with a strong future roadmap: Strides Pharma Science, Ajanta Pharma and Divi’s Laboratories. Compare price, valuation, return on equity and revenue growth as of 23 October 2026.
-
3 Finished Dosage Generics, Anti-Retroviral and Active Ingredient Leader and Complex Oncology Generics Stocks With a Strong Future Roadmap: Strides Pharma Science, Laurus Labs and Natco Pharma
- October 23, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
US Generics and Complex Oncology Drug Stocks with a strong future roadmap: Strides Pharma Science, Laurus Labs and Natco Pharma. Compare price, valuation, return on equity and revenue growth as of 22 October 2026.
-
3 Ingredients and Custom Manufacturing, Oral Solid Generics and Large Branded Generics Stocks With a Strong Future Roadmap: Neuland Laboratories, Strides Pharma Science and Dr. Reddy’s Laboratories
- October 22, 2026
- Posted by: Chaitanya Auti
- Category: Best Stocks
Pharma Ingredient and Generic Formulation Stocks with a strong future roadmap: Neuland Laboratories, Strides Pharma Science and Dr. Reddy’s Laboratories. Compare price, valuation, return on equity and revenue growth as of 21 October 2026.
-
3 Acute Therapy Franchise, Chronic Care Leader and Regulated Market Generics Stocks With a Strong Future Roadmap: Alkem Laboratories, Torrent Pharmaceuticals and Strides Pharma Science
- October 21, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
Pharma Franchise Stocks with a strong future roadmap: Alkem Laboratories, Torrent Pharmaceuticals and Strides Pharma Science. Compare price, valuation, return on equity and revenue growth as of 20 October 2026.
-
3 Oral Generics, Biotech Research Services and Fermentation APIs Stocks With a Strong Future Roadmap: Strides Pharma Science, Anthem Biosciences and Concord Biotech
- October 21, 2026
- Posted by: Lakshit Sharma
- Category: Best Stocks
Biotech and Generics Stocks with a strong future roadmap: Strides Pharma Science, Anthem Biosciences and Concord Biotech. Compare price, valuation, return on equity and revenue growth as of 20 October 2026.
-
3 Hospital Pharma, Generic Formulations and Domestic Brands Stocks With a Strong Future Roadmap: Emcure Pharmaceuticals, Strides Pharma Science and Mankind Pharma
- October 21, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
Formulation Pharma Stocks with a strong future roadmap: Emcure Pharmaceuticals, Strides Pharma Science and Mankind Pharma. Compare price, valuation, return on equity and revenue growth as of 20 October 2026.
-
3 Generic Pharma Exporter Stocks With a Strong Future Roadmap: Strides Pharma Science, Granules India and Marksans Pharma
- October 7, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
Strides Pharma Science, Granules India and Marksans Pharma compared on growth, margins, debt and valuation, with the roadmap and risks investors should track.